Are SSRIs a cost-effective alternative to tricyclics?

Area of Science:

• Pharmacoeconomics
• Clinical Psychiatry
• Health Services Research

Background:

• Selective serotonin reuptake inhibitors (SSRIs) are generally more expensive than tricyclic antidepressants (TCAs).
• Previous reports have suggested potential cost-effectiveness of SSRIs due to better tolerability and safety in overdose.
• The economic comparison between these antidepressant classes remains a critical area of investigation.

Purpose of the Study:

• To systematically review evidence comparing the cost-effectiveness of SSRIs and TCAs.
• To evaluate the validity of claims regarding the economic advantages of SSRIs.
• To identify research gaps in understanding the economic impact of different antidepressant treatments.

Main Methods:

• Systematic review of randomized controlled trials (RCTs), meta-analyses, and cost-effectiveness studies.
• Analysis focused on studies comparing SSRIs and TCAs for depression.
• Assessment of methodological quality of included economic evaluations.

Main Results:

• No RCTs included economic analyses; many had methodological flaws.
• Meta-analyses indicate equivalent clinical efficacy between SSRIs and TCAs, with slightly lower dropout rates for SSRIs.
• Existing cost-effectiveness studies rely on flawed modeling, overestimating attrition differences and treatment failure costs.
• Economic impact of suicide is difficult to assess due to rarity.

Conclusions:

• Current evidence does not support the claim that SSRIs are more cost-effective than TCAs.
• Further research, specifically prospective cost-effectiveness studies within large primary care RCTs, is required.
• The economic debate on antidepressant choice necessitates robust, real-world data.